Agios Pharmaceuticals Inc
NASDAQ:AGIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Agios Pharmaceuticals Inc (AGIO) under the Base Case is 43.8 USD per share.
Compared with the current market price of 30.15 USD, the stock appears
Undervalued by 31% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Agios Pharmaceuticals Does
Agios Pharmaceuticals is a biotech company that develops medicines for rare blood disorders. Its main approved drug is Pyrukynd, a pill used to treat certain inherited anemia conditions by helping red blood cells make energy more efficiently. The company also keeps working on other drug candidates in rare hematology, using the same idea of targeting cell metabolism.
- Headquarters
- United States of America US
- Employees
- 539
- IPO date
- Jul 24, 2013
Continue AGIO Research
Decided on Agios Pharmaceuticals? Get an email when AGIO reaches the price you’d buy at. Free with an account.
Other Agios Pharmaceuticals listings
What is the Intrinsic Value of one AGIO stock?
The intrinsic value for
Agios Pharmaceuticals Inc (AGIO) under the Base Case is 43.8 USD.
Is AGIO stock undervalued or overvalued?
Compared with the current market price of 30.15 USD, the stock appears Undervalued by 31% .